Addition of Greenleaf Caps Series of Appointments
to Strengthen Commercial Organization
GAITHERSBURG, Md., May 22 /PRNewswire-FirstCall/ -- MedImmune, Inc.
(Nasdaq: MEDI) today announced that Peter S. Greenleaf has joined the
management team as senior vice president, marketing and sales. In this
position, he is responsible for leading MedImmune's global commercial
organization and developing strategies to ensure the successful
commercialization of the company's current and future product portfolio.
"The addition of Peter to our team is the capstone of a series of steps
taken to strengthen our commercial organization and to prepare for the
opportunities that lie ahead," said David M. Mott, chief executive officer and
president. "Peter is a high-energy professional who brings both marketing and
sales management experience as well as an entrepreneurial biotechnology
background, which he will apply to leading our more than 550 professionals in
the marketing and sales organization. Peter's initial focus will be on
ensuring a successful 2006-2007 season for Synagis(R) (palivizumab). He will
concurrently lead the preparations for the potential launches of next-
generation FluMist(R) (Influenza Virus Vaccine Live, Intranasal) in 2007 and
MedImmune's next-generation anti-RSV monoclonal antibody, Numax(TM), in 2008.
Peter will also focus on continuing to build our commercial capabilities and
portfolio in the oncology marketplace where we currently sell Ethyol(R)
Prior to joining MedImmune, Mr. Greenleaf was a vice president for
Centocor, Inc., with responsibility for the company's gastroenterology
commercial operation including sales, marketing, strategic planning and
business development. He joined Centocor's cardiovascular division in 1998
and later moved into the immunology business, holding a number of positions
with increasing responsibility in sales and marketing. Previously, he was
employed in sales and marketing capacities with Boehringer Mannheim
Corporation and US Healthcare, Inc. Mr. Greenleaf holds a bachelor's degree
from Western Connecticut State University and a master's in business
administration from St. Joseph's University.
Mr. Greenleaf is the sixth recent senior-level appointment on the
commercial side of MedImmune's business, including R. Michael Smullen to
senior vice president, sales; Frank D. Czworka, Jr., to vice president, sales,
infectious disease; John J. Trizzino to vice president, trade and
distribution; Mark C. Twyman to vice president and general manager, vaccines;
and Douglas B. Willner to vice president, sales training.
About MedImmune, Inc.
MedImmune strives to provide better medicines to patients, new medical
options for physicians, rewarding careers to employees, and increased value to
shareholders. Dedicated to advancing science and medicine to help people live
better lives, the company is focused on the areas of infectious disease,
cancer and inflammatory diseases. With more than 2,300 employees worldwide,
MedImmune is headquartered in Maryland. For more information, visit the
company's website at http://www.medimmune.com.
SOURCE MedImmune, Inc.
CONTACT: Media: Kate Barrett, +1-301-398-4320, or Investors: Peter
Vozzo, +1-301-398-4358, both of MedImmune, Inc.